Bio-Connect

Apolipoprotein E

16-16-120500
Athens Research
Protein IDP02649
Product group Proteins / Signaling Molecules
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Athens Research
  • Product Name
    Apolipoprotein E
  • Delivery Days Customer
    9
  • Applications Supplier
    In Vitro Diagnostics, Alzheimer's
  • Certification
    Research Use Only
  • Estimated Purity
    ≥95% by SDS-PAGE
  • Protein IDP02649
  • Protein Name
    Apolipoprotein E
  • Scientific Description
    Apolipoprotein E (ApoE) is a glycoprotein with three major isoforms (E2, E3, E4) that mediates lipid transport by binding low-density lipoprotein receptors (LDLR, LRP, VLDLR) to facilitate cholesterol redistribution. Its receptor-binding domain (residues 140–150), rich in lysines and arginines, enables interactions critical for lipoprotein clearance and lipid homeostasis. Beyond lipid metabolism, ApoE modulates immune responses by suppressing T-cell activation via reduced MHC class II expression on antigen-presenting cells and influences neurobiology through astrocyte-derived cholesterol transport to neurons. Elevated ApoE levels (normal plasma: ~5 mg/dL) are observed during peripheral nerve injury, where it aids tissue repair by coordinating lipid reutilization; however, the E4 isoform delays regeneration and neuromuscular reinnervation. Clinically, ApoE2 homozygosity or mutations like Arg145Cys cause familial type III hyperlipoproteinemia, characterized by bèta-VLDL accumulation and xanthomas. The epsilon4 allele is a major genetic risk factor for Alzheimer’s disease, promoting Abèta aggregation and impairing synaptic function. ApoE4 also exacerbates cardiovascular risk by elevating LDL-C and carotid intima-media thickness. Emerging roles include modulating melanoma cell states, where ApoE secretion by MITF-high tumors confers ferroptosis resistance via lipid peroxidation suppression. Therapeutically, ApoE-targeted strategies include antisense oligonucleotides reducing ApoE4 levels in tauopathies. LXR/RXR agonists enhancing apoE lipidation, and mimetic peptides like CN-105 mitigating neuroinflammation post-brain injury. These innovations highlight ApoE’s dual potential as a biomarker and therapeutic target across neurodegenerative, metabolic, and oncological disorders.
  • Shelf life instruction
    more then 1 year
  • Source
    Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
  • Storage Instruction
    ≤ -80° C
  • UNSPSC
    41116100

References

  • Deng, M. et al., (2018), 'LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration', Nature, 562: pp 605–609
    Read this paper
  • Ulatowski, L., et al., (2022), 'The tocopherol transfer protein TTP mediates Vitamin Vitamin E trafficking between cerebellar astrocytes and neurons', J. Biol. Chem., 298(3): pp 101712.
    Read this paper
  • Vogt, L. M., et al., (2020), 'Apolipoprotein E Triggers Complement Activation in Joint Synovial Fluid of Rheumatoid Arthritis Patients by Binding C1q', J Immunol., 204: pp 2779-2790.
    Read this paper
  • Wagar, Z. L., et al., (2017), 'Low density lipopolyprotein inhibits flavivirus acquisition in Aedes aegypti', Insect Molecular Biology, 26(6): pp 734–742
    Read this paper